Target intelligence / Profile preview

Gastric and duodenal mucosal surface

Molecular classification
Other (epithelial tissue, not a molecular target)
01

Overview

The gastric and duodenal mucosal surfaces are the innermost layers of the stomach and duodenum, made of simple columnar epithelial cells overlying a layer of mucus that protects the tissue from acidic, enzymatic, and mechanical injury. In the stomach, these surface mucous (foveolar) cells secrete a thick, alkaline mucus to shield the epithelium from hydrochloric acid and digestive enzymes. In the duodenum, surface enterocytes and goblet cells secrete mucus and bicarbonate to neutralize gastric acid and support nutrient absorption. Disruption of this barrier leads to diseases such as ulcers, gastritis, and duodenitis. As a term, "gastric/duodenal mucosal surface" awkwardly combines two distinct but related anatomical structures and does not represent a conventional drug target entity (like a protein, receptor, or transporter). Therapies interact with the mucosa indirectly by modifying acid production, promoting mucus secretion, or eradicating pathogens. If you are seeking specific protein targets within this tissue (e.g., prostaglandin receptors, H+/K+ ATPase), these should be named specifically rather than referring generically to the mucosal surface.

Other names
gastric mucosaduodenal mucosagastric epitheliumduodenal epitheliumgastric surface epitheliumfoveolar epithelium (for stomach)intestinal villous epithelium (for duodenum)
02

Mechanism of action

Increase mucus or bicarbonate secretion (protectants) Reduce acid secretion (proton pump inhibitors, H2 blockers) Neutralize acid (antacids) Promote ulcer healing Direct epithelial toxicity (NSAIDs)

03

Biological functions

Physical barrier functionSecretion of protective mucusMaintenance of acidic and enzymatic environment (stomach)Absorption and neutralization of gastric contents (duodenum)First-line immune defense
04

Disease associations

Peptic ulcer diseaseGastritisDuodenitisInfection (e.g., *Helicobacter pylori*)Malignancy (gastric cancer, adenocarcinoma)Inflammatory disease (Crohn’s, celiac disease)
05

Safety considerations

Ulceration risk with NSAIDsInfection risk with *H. pylori* or immunosuppressionBleeding risk (if compromised)Cancer risk with chronic injury/inflammation
06

Interacting drugs

Proton pump inhibitors (omeprazole, lansoprazole)

5 more in the full profile.

07

Biomarkers

*H. pylori* tests (antigen, urea breath, serology)Fecal occult blood (for ulceration)Endoscopic biopsy markers (mucosal integrity, inflammation)

Beyond the preview

Go deeper on Gastric and duodenal mucosal surface.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric and duodenal mucosal surface.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call